24 results
ARS
2022 FY
PNT
POINT Biopharma Global Inc.
1 May 23
Annual report to shareholders
1:52pm
of manufacturing errors, could result in patient injury or death, product shortages, product recalls or withdrawals, delays or failures in product testing … cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination
8-K
EX-99.2
PNT
POINT Biopharma Global Inc.
12 Sep 22
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
7:54am
0.0 0 0.0 Acute kidney injury 0 0.0 0 0.0 1† 3.7 0 0.0 Vomiting 0 0.0 0 0.0 0 0.0 0 0.0 Laboratory abnormalities Lymphocyte count decreased 1 3.7 0 … 0.0 0 0.0 0 0.0 0 0.0 *Includes fatigue and asthenia. †Acute kidney injury leading to hospitalization resolved the following day; this event
DEF 14A
PNT
POINT Biopharma Global Inc.
28 Apr 22
Definitive proxy
8:36am
Federations of Canada National Young Leadership Award of Distinction, the Special Recognition Award by Brain Injury Canada and Bernard Gross Leadership Award
424B3
k0vsfwb9qz2uduy6
31 Mar 22
Prospectus supplement
11:42am
POS AM
8em8il8som 82a
25 Mar 22
Prospectus update (post-effective amendment)
8:41am
424B3
99qhd3hd
5 Aug 21
Prospectus supplement
4:26pm
424B3
0n2 sngao9f
9 Jun 21
Prospectus supplement
4:42pm
S-4/A
EX-10.13
ufh42bkizi1
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4/A
EX-10.16
2n8jqz2h8s1zp
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4/A
EX-10.19
4lzqqtkjoj8kd12roluh
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4/A
231ad6qrcd 7kgz
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm